SMTL ID : 4eev.1

Crystal structure of c-Met in complex with LY2801653

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.80 Å

Oligo State

monomer

Ligands

1 x L1X: N-(3-fluoro-4-{[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide(Non-covalent)

L1X.1: 23 residues within 4Å: Chain A: I.55, G.56, V.63, A.79, K.81, E.98, I.101, M.102, F.105, V.110, L.111, L.128, P.129, Y.130, M.131, L.166, F.171, H.173, M.182, V.191, A.192, D.193, F.194 13 PLIP interactions: 13 interactions with chain A Hydrophobic interactions: A:I.55, A:A.79, A:I.101, A:F.105, A:V.110, A:L.128, A:F.171, A:D.193, A:F.194 Hydrogen bonds: A:M.131, A:D.193 Water bridges: A:K.81 pi-Stacking: A:F.194

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Yan, S.B. et al., LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs (2013)

Release Date

2013-04-10

Peptides

Hepatocyte growth factor receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Hepatocyte growth factor receptor